The protein which leads to Alzheimer's disease

A study published in the issue of Molecular Psychiatry on October 18th suggests that specific proteins with cognitive decline in Alzheimer's disease also play a role in schizophrenia. This means that a drug of target protein can treat a variety of neuropsychiatric disorders.

Researchers at Yale University have been studying the role of synapses in brain cells by recombinant mouse proteins. Excessive amounts of STEP protein are found in the brains of human and animal models of Alzheimer's disease, Parkinson's disease, fragile X syndrome and schizophrenia. This increase leads to disruption of synaptic function, leading to cognitive impairment of these diseases.

In previous studies, he and colleagues had shown that reducing STEP or using drugs to suppress STEP is beneficial in reducing cognitive impairment in Alzheimer's disease mice. In addition, they also found that a high level of STEP content was found in the stem cells obtained from the skin of two groups of patients with schizophrenia. For these biochemical and electrophysiological abnormalities of human stem cell cells, STEP inhibitors were administered.

Although early drug trials of Alzheimer's disease have proved difficult to be developed for clinical use, Professor Rambus and colleagues at Yale University are developing an inhibitor. If successful, this study may be of more practical therapeutic value. Flarebio offers good-quality recombinant proteins such as recombinant ECE1.